Pharmaceutical company Moderna Inc (NASDAQ: MRNA) announced on Tuesday that it has achieved successful Phase 3 trial results for mRNA-1283, its next-generation COVID-19 vaccine. Compared to its licensed vaccine mRNA-1273.222, mRNA-1283 induces a stronger immune response against SARS-CoV-2, particularly in individuals over 65.
The NextCOVE trial involved over 11,400 participants aged 12 and above across the US, UK and Canada. mRNA-1283 demonstrates a similar safety profile to Moderna's approved COVID-19 vaccines.
mRNA-1283's storage, shelf life, and pre-filled syringe presentation could ease healthcare provider burden and enhance accessibility in various settings. Detailed trial data will be presented at Moderna's Vaccines Day event on 27 March 2024.
Moderna's mRNA platform has revolutionised medicine development, delivering rapid and efficient solutions for infectious diseases, immuno-oncology, rare diseases and autoimmune conditions. The company's mission is to create a healthier future through innovative mRNA medicines.
Quest Diagnostics acquires OhioHealth lab assets
Exelixis and Merck collaborate on clinical development of zanzalintinib
BD launches automated reagent kit to streamline single-cell discovery studies
Transgene's Phase II trial of TG4001 falls short of primary objective
SkylineDx reveals new data from the MERLIN_001 prospective US multi-centre trial
Turnstone Biologics announces strategic restructuring
Pfizer's TALZENNA plus XTANDI shows promise in prostate cancer treatment
GenesisCare UK selects RayStation for radiotherapy system upgrade
Boehringer Ingelheim and Circle Pharma collaborate on cancer treatment
Petauri launches medical communications platform Petauri Advance
Bayer and MOMA Therapeutics enter oncology collaboration
GBI Biomanufacturing agrees manufacturing collaboration with Allterum Therapeutics
MediLink enters clinical trial collaboration and supply agreement with Amgen